Syros Pharmaceut Stock Price, News & Analysis

Syros Pharmaceuticals (SYRS) reported its Q2 2021 financial results, showing revenues of $5.2 million, up from $3.2 million in Q2 2020. The net loss was $22.5 million, or $0.36 per share. Cash, cash equivalents, and marketable securities totaled $195.3 million as of June 30, 2021. The company is advancing its portfolio in targeted hematology and selective CDK inhibition, with significant milestones including collaborations with Roche for SY-5609, a selective CDK7 inhibitor. Upcoming trials are set to begin in the second half of 2021, indicating a strong focus on addressing unmet medical needs.

Syros Pharmaceuticals (NASDAQ:SYRS) has established a clinical supply agreement with Roche to provide SY-5609, an oral CDK7 inhibitor, for a combination therapy study in Roche's Phase 1/1b INTRINSIC trial. This trial targets colorectal cancer patients and explores SY-5609's efficacy in conjunction with atezolizumab. Roche will sponsor the study and cover associated costs, while Syros retains rights to SY-5609 and will have access to study data. Previous preclinical studies suggest that SY-5609 may significantly enhance the effectiveness of immunotherapy in BRAF-mutant colorectal cancer.

Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on August 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. Interested parties can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 4156527. The call can also be accessed via the Syros website, with a replay available for 30 days post-event. Syros is focused on developing innovative gene expression control therapies for cancer and other serious diseases.

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2021 Life Sciences Conference on June 16 at 1:00 p.m. ET. A live webcast will be available on the Syros website, with an archived replay accessible for 30 days post-event. Syros focuses on innovative gene expression control with a robust clinical pipeline, including SY-1425 for myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors.

Syros Pharmaceuticals (NASDAQ:SYRS) announced a three-part KOL webcast series focusing on its investigational targeted therapies in hematology. The series will cover SY-1425 for myelodysplastic syndrome and acute myeloid leukemia, along with SY-2101 for acute promyelocytic leukemia. Presentations will feature Syros leaders and guest KOLs, highlighting recent advancements and unmet needs in these diseases. Webcasts are scheduled for May 26, June 22, and July 20, 2021, each starting at 8:30 AM ET. Archived replays will be available post-event.

Syros Pharmaceuticals (NASDAQ:SYRS) reported Q1 2021 financial results, showing revenues of $4.8 million, up from $2.4 million in Q1 2020. The company is progressing in hematology with a Phase 3 trial of SY-1425 for RARA-positive higher-risk MDS, and planning to initiate further trials for SY-1425 and SY-2101 in H2 2021. R&D expenses increased to $20.0 million due to clinical advancements, while G&A expenses rose to $5.7 million. Net loss decreased to $14.2 million, or $0.23 per share. Cash reserves stood at $222.1 million, expected to fund operations through 2023.

Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on May 6, 2021, at 8:30 a.m. ET to discuss its first-quarter financial results and provide a corporate update. Investors can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 5770919. The event will also be available via webcast on their website, with an archive accessible for 30 days post-event. Syros is focused on gene expression control and has a strong clinical pipeline, including SY-1425 for myelodysplastic syndrome and SY-2101 for acute promyelocytic leukemia.

Syros Pharmaceuticals (SYRS) reported financial results for Q4 and the full year 2020, achieving revenues of $5.7 million in Q4 and $15.1 million for the year. The net loss for Q4 was $30.1 million ($0.62 per share), compared to $19.7 million in Q4 2019. Cash and equivalents stood at $174 million as of December 31, 2020. The company announced significant advancements in its clinical programs, including initiating Phase 2 trials for SY-1425 in AML and SY-2101 in APL. Syros expects to continue funding its operations through 2023 with its current cash position.

Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on March 4, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results. Investors can dial 866-595-4538 for domestic or 636-812-6496 for international access, using conference ID 4472467. A replay will be available for 30 days post-event. Syros is focused on developing treatments that modulate gene expression, with a clinical-stage pipeline that includes innovative therapies like SY-1425 for myelodysplastic syndrome and SY-5609 for solid tumors.